Serum Lipoprotein Abnormalities in Ischaemic Heart Disease and Peripheral Vascular Disease

1974 ◽  
Vol 46 (2) ◽  
pp. 12P-12P
Author(s):  
Barry Lewis ◽  
Gunnar Sigurdsson ◽  
Alan Chait ◽  
Celia Oakley ◽  
John Birkhead ◽  
...  
Keyword(s):  
Heart Disease ◽  
Vascular Disease ◽  
Ischaemic Heart Disease ◽  
Peripheral Vascular Disease ◽  
Serum Lipoprotein ◽  
Peripheral Vascular

Intravenous Fat-Tolerance Test in Ischaemic Heart Disease and Peripheral Vascular Disease

1976 ◽  
Vol 51 (4) ◽  
pp. 415-420
Author(s):  
B. Lewis ◽  
A. C. Onitiri ◽  
I. D. P. Wootton ◽  
A. Chait ◽  
G. Sigurdsson ◽  
...  
Keyword(s):  
Heart Disease ◽  
Vascular Disease ◽  
Ischaemic Heart Disease ◽  
Peripheral Vascular Disease ◽  
Turnover Rate ◽  
Serum Triglyceride ◽  
Tolerance Test ◽  
Peripheral Vascular ◽  
Fat Tolerance Test ◽  
Normal Men

1. The intravenous fat-tolerance test and serum lipid and lipoprotein measurements were carried out in ninety-three normal subjects, fifty-one patients with ischaemic heart disease and thirty patients with peripheral vascular disease. 2. The fractional turnover rate of exogenous triglyceride was significantly slower in patients with ischaemic heart disease and in patients with peripheral vascular disease than in normal men. The rate was also slower in normal men than normal women. 3. Serum triglyceride and cholesterol concentrations were higher in both vascular disease groups than in control subjects. 4. The proportion of both groups of patients who had a subnormal fractional turnover rate of exogenous triglyceride was 35%, and 32% of patients had hypertriglyceridaemia in the fasting state; 27% of patients were hypercholesterolaemic. 5. Although the intravenous fat-tolerance test did not provide significantly better discrimination between cardiovascular patients and control subjects than did measurement of serum triglyceride, the results suggest that hypertriglyceridaemia in such patients may be separable into a group in which impaired triglyceride clearance may be partly responsible, and a group in which overproduction of serum triglyceride may be the major mechanism of the hyperlipidaemia.

Macroangiopathy in type II diabetes

1983 ◽  
Vol 104 (4_Suppl) ◽  
pp. S75-S78
Author(s):  
Antti Aro
Keyword(s):  
Coronary Heart Disease ◽  
Heart Disease ◽  
Vascular Disease ◽  
Peripheral Vascular Disease ◽  
Type Ii Diabetes ◽  
Clinical Manifestations ◽  
Diabetic Patients ◽  
Type Ii ◽  
Peripheral Vascular ◽  
Middle Aged

ABSTRACT. Macroangiopathy is the most important cause of mortality and morbidity in type II diabetes. The atherosclerotic process in diabetes is similar to that found in non-diabetic subjects, but the laesions are more extensive and the clinical manifestations are more common in diabetic subjects than in the non-diabetic population. In diabetic patients from different populations, the prevalence of macroangiopathy is variable, and the relative frequency follows the pattern found in the respective non-diabetic populations. The relative risk of large vessel disease is in most populations higher for female than for male diabetics. Coronary heart disease is the most important manifestation of macroangiopathy while cerebrovascular disease and peripheral vascular disease are less frequent, although all these manifestations occur at increased frequency among middle-aged diabetic subjects. The incidence of peripheral vascular disease seems to increase with increasing duration of diabetes in middle-aged subjects, whereas coronary heart disease is particularly frequent in type II diabetes already at the time of the diagnosis. Key words: atherosclerosis, complications, diabetes mellitus, macroangiopathy, mortality.

Circulatory uses of prostaglandins

1984 ◽  
Vol 22 (26) ◽  
pp. 101-103
Keyword(s):  
Fatty Acids ◽  
Congenital Heart Disease ◽  
Arachidonic Acid ◽  
Heart Disease ◽  
Vascular Disease ◽  
Peripheral Vascular Disease ◽  
Congenital Heart ◽  
Peripheral Vascular ◽  
Naturally Occurring

Prostaglandins (PGs) are naturally-occurring fatty acids synthesised from arachidonic acid by cyclo-oxygenase enzymes. Two PGs with circulatory actions, alprostadil (PGE1; Prostin VR - Upjohn) and epoprostenol (prostacyclin, PGI2; Flolan - Wellcome, Cyclo-Prostin - Upjohn) are marketed in Britain. Both have already found a place; alprostadil for neonates with congenital heart disease, epoprostenol for use in extracorporeal circulations and in patients with severe peripheral vascular disease.

Low Cost Non-Invasive Instrument for Heart Disease and Peripheral Vascular Disease Detection

2006 ◽  
Author(s):  
Narongrit maneejiraprakarn ◽  
Phakakorn Panpho ◽  
Duangduan Boonthong ◽  
Piyanut Thitiwuthikiat ◽  
Jeerasuda Koseeyaporn ◽  
...  
Keyword(s):  
Heart Disease ◽  
Vascular Disease ◽  
Peripheral Vascular Disease ◽  
Low Cost ◽  
Disease Detection ◽  
Peripheral Vascular ◽  
Non Invasive
Sign in / Sign up

Export Citation Format

Share Document